Valentis Pharma - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 12,188,926 | 13,889,548 | 16,436,078 | 19,391,919 | -9,675 | - | - | - |
| Profit before tax | 1,447,794 | 1,579,100 | 1,939,128 | 2,884,681 | -352,499 | -82,689 | -35,777 | -30,824 |
| Net profit | 1,228,343 | 1,340,533 | 1,654,656 | 2,442,727 | -367,614 | -82,689 | -35,777 | -30,824 |
| Equity | 1,246,681 | 1,387,214 | 1,741,870 | 2,584,597 | -283,017 | 234,294 | 198,516 | 167,692 |
| Liabilities | 6,593,914 | 7,257,845 | 8,728,929 | 7,190,594 | 621,226 | 2,635 | 2,518 | 2,435 |
| Non-current assets | 102,511 | 78,635 | 75,330 | 139,995 | 83,730 | 83,730 | 83,730 | 83,730 |
| Current assets | 7,799,626 | 8,603,201 | 10,497,604 | 9,775,407 | 254,479 | 153,199 | 117,304 | 86,397 |
| Total assets | 7,902,137 | 8,681,836 | 10,572,934 | 9,915,402 | 338,209 | 236,929 | 201,034 | 170,127 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 14,503 | - | 2,212 |
| Social insurance contributions | - | - | - | - | - | 13,719 | 1,702 | - |
|
Financial indicators
|
||||||||
| Revenue change y/y | +15.1% | +14.0% | +18.3% | +18.0% | - | - | - | - |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 15.5% | 15.4% | 15.6% | 24.6% | -108.7% | -34.9% | -17.8% | -18.1% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 98.5% | 96.6% | 95.0% | 94.5% | - | -35.3% | -18.0% | -18.4% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 10.1% | 9.7% | 10.1% | 12.6% | - | - | - | - |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 11.9% | 11.4% | 11.8% | 14.9% | - | - | - | - |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 5.3 | 5.2 | 5.0 | 2.8 | - | 0.0 | 0.0 | 0.0 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 409,712 | 452,920 | 527,360 | 651,829 | - | - | - | - |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Valentis Pharma - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2023-03-16 | 2023-03-20 | 1703.65 |
Valentis Pharma - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2025-01-01 | 2025-01-01 | 4.82 |
| 2024-12-17 | 2024-12-31 | 1.84 |
| 2024-12-08 | 2024-12-16 | 1.69 |
| 2024-12-04 | 2024-12-07 | 0.94 |
| 2024-12-03 | 2024-12-03 | 196.54 |
| 2024-11-21 | 2024-12-02 | 0.89 |
| 2024-11-08 | 2024-11-20 | 49.87 |
| 2024-10-02 | 2024-10-13 | 91.51 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.